TYCC
LGND icon

Texas Yale Capital Corp’s Ligand Pharmaceuticals LGND Stock Holding History

Texas Yale Capital Corp’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,344
Closed -$420K – 457
2019
Q1 		$420K Buy
5,344
+2,806
+111% +$213K 0.02% 421
2018
Q4 		$215K Buy
+2,538
New +$271K 0.02% 394

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Texas Yale Capital Corp's LGND Position: Q2 2019 in Review

Texas Yale Capital Corp sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 5,344 shares — an estimated $420K sold.

Texas Yale Capital Corp first reported a position in LGND in Q4 2018 and held it in 2 quarters. The position peaked at $420K in Q1 2019. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

  • Texas Yale Capital Corp reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Texas Yale Capital Corp sold 5,344 Ligand Pharmaceuticals shares in Q2 2019, an estimated $420K.
  • Texas Yale Capital Corp first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Texas Yale Capital Corp's Ligand Pharmaceuticals position peaked at $420K in Q1 2019.
  • 305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Texas Yale Capital Corp's 13F filing for Q2 2019, filed 24 Jul 2019.